LIRAGLUTIDE
| Brand name | SAXENDA |
|---|---|
| Active ingredient | LIRAGLUTIDE |
| Strength | 18MG/3ML (6MG/ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | December 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9968659*PED | July 2037 | — |
| 9968659 | January 2037 | use U-2438 |
| 8114833*PED | February 2026 | — |
| 8114833 | August 2025 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.